- ?? Blog ActionCovid1984.org
- ?? Irish Examiner
- Inverse
- ?? Gript media
- Blake-Lemoine - LaMBDA
- ?? Over Dee Wall
- The Defender News
- ?? BreakingNews.ie
- Dr Vernon Coleman
- Rebel News
- Vaccine Choice Canada NEWS
- SHFT Plan
- The Expose
- ?? Robert Pierzyński PJ
- James Roguskii - Substack
- ?? The Burkean
- Liberty Tactics IM
- stewpeters.com
- Technocracy News
- Interesting Engineering
- ?? Media Hub Ireland
- ?? The Irish Inquiry
- ?? Andy Heasman
- ?? GriptMedia
- ?? WeThePeople.ie
- ?? Action-Covid-1984
- ?? Lets wake up our Capital
- ?? Lets Wake Up Call!!!
- WW Freedom Rallies
- Piers Corbyn
- ?? Tracey OMahony
- ?? The Irish Git
- eIRe is falling
- Peter Madden Channel
- rish Farmers,Food & Family
- Gemma O'Doherty
What's new
What's new
Questions and answers for biological medicinal products
Questions and answers for biological medicinal products
25 September 2026
Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Date of authorisation: 22/09/2023, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Date of authorisation: 22/09/2023, Revision: 4, Status: Authorised
25 September 2026
Human medicines European public assessment report (EPAR): Celldemic, zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures), Date of authorisation: 19/04/2024, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Celldemic, zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures), Date of authorisation: 19/04/2024, Revision: 1, Status: Authorised
25 September 2026
Human medicines European public assessment report (EPAR): Incellipan, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures), Date of authorisation: 19/04/2024, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Incellipan, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures), Date of authorisation: 19/04/2024, Revision: 2, Status: Authorised
25 September 2026
Human medicines European public assessment report (EPAR): Gobivaz, golimumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Gobivaz, golimumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
25 September 2026
Human medicines European public assessment report (EPAR): Suboxone, buprenorphine,naloxone, Date of authorisation: 26/09/2006, Revision: 24, Status: Withdrawn
Human medicines European public assessment report (EPAR): Suboxone, buprenorphine,naloxone, Date of authorisation: 26/09/2006, Revision: 24, Status: Withdrawn
25 September 2026
Human medicines European public assessment report (EPAR): Tolvaptan Accord, tolvaptan, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Tolvaptan Accord, tolvaptan, Revision: 2, Status: Authorised
25 September 2026